EGTX — Egetis Therapeutics AB (publ) Cashflow Statement
0.000.00%
Last trade - 00:00- SEK1.89bn
- SEK1.70bn
- SEK57.60m
Annual cashflow statement for Egetis Therapeutics AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -61.4 | -179 | -105 | -194 | -327 |
| Depreciation | |||||
| Non-Cash Items | -1.15 | 2.03 | 0.228 | 9.4 | 17.7 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.282 | 42.1 | -28.3 | 10.9 | 30.7 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -62.6 | -135 | -130 | -174 | -278 |
| Capital Expenditures | — | -0.024 | -0.172 | 0 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -59.5 | -5.79 | -1.7 | 0 |
| Acquisition of Business | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | -59.5 | -5.96 | -1.7 | 0 |
| Financing Cash Flow Items | -4.32 | -22.1 | 0 | -12.6 | -26.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 86.7 | 228 | -8.9 | 156 | 459 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 25.2 | 32.8 | -144 | -16.3 | 176 |